Tubulis
Seedtable Score
56
Startups
3
Funding Rounds
8
Investors
$216.22m
Money raised
Overview
Tubulis has notable potential in developing chemotherapeutic drugs targeting cancer and chronic diseases. Based in Munich, the company focuses on innovative drug development to address limitations of existing chemotherapy treatments. Using a B2B model, Tubulis partners with larger pharmaceutical companies and healthcare providers, channeling their technological advancements into the market. Supported by investors such as Nextech Invest and EQT Life Sciences, Tubulis enjoys robust financial backing and industry credibility. Their specialized approach aims to offer more effective and targeted treatments, positioning them competitively against traditional chemotherapy options and potentially accelerating progress in combating serious health conditions.
- Website: https://tubulis.com
- Business model: b2b
- Company size: 11 - 51 employees
- Headquarters: Munich, Germany
- Founded: 2012
- Social accounts: Linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Investors (8)
Funding
Funding series
Funding Series Analysis
The company Tubulis has raised a total of $216.22m in funding over 3 rounds.
Key Insights:
- Unknown: $64.98m
- Series A: $12.24m
- Series B: $139m
Tubulis Series A (2020, $12M)
$12.24m
Tubulis Unknown (2022, $64M)
$64.98m
Tubulis Series B (2024, $139M)
$139m